Bioxyne Limited (BXN) Price & Analysis

Q: What was Bioxyne Limited’s price range in the past 12 months?

Bioxyne Limited lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.

Q: What is Bioxyne Limited’s market cap?

Bioxyne Limited’s market cap is AU$134.39M.

Q: When is Bioxyne Limited’s upcoming earnings report date?

Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 180 days.

Q: How were Bioxyne Limited’s earnings last quarter?

Bioxyne Limited released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.

Q: Is Bioxyne Limited overvalued?

According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Bioxyne Limited pay dividends?

Bioxyne Limited does not currently pay dividends.

Q: What is Bioxyne Limited’s EPS estimate?

Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Bioxyne Limited have?

Bioxyne Limited has 2,239,909,200 shares outstanding.

Q: What happened to Bioxyne Limited’s price movement after its last earnings report?

Bioxyne Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.385%.

Q: Which hedge fund is a major shareholder of Bioxyne Limited?

Currently, no hedge funds are holding shares in AU:BXN

Compare

13 Followers

BXN Stock Chart & Stats

AU$0.04

<AU$0.01(4.17%)

At close: Jan 09 4:00 PM EST

AU$0.04

<AU$0.01(4.17%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.06

Previous CloseN/A

Volume631.90K

Average Volume (3M)4.35M

Market Cap

AU$134.39M

Enterprise ValueAU$134.22M

Total Cash (Recent Filing)AU$7.60M

Total Debt (Recent Filing)AU$7.43M

Price to Earnings (P/E)14.6

Beta1.54

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding2,239,909,200

10 Day Avg. Volume2,483,521

30 Day Avg. Volume4,348,514

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)7.54

Price to Sales (P/S)2.90

P/FCF Ratio22.82

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained 77% revenue growth signals expanding product adoption and market penetration in regulated medicinal cannabis markets. This top-line momentum supports scale economics, strengthens negotiating power with partners and distributors, and underpins multi-quarter growth visibility.

Operating ProfitabilityDouble-digit EBIT and net margins indicate durable operational control and ability to convert revenue into earnings. For a life-science consumer products business, this margin profile provides reinvestment capacity for R&D and market expansion and a buffer against cyclical revenue swings.

Balance Sheet & Cash GenerationVery low leverage with high ROE and a dramatic free-cash-flow improvement point to strong financial flexibility and efficient capital use. High cash conversion ratios support sustainable funding for capex, working capital and product rollouts without reliance on dilutive financing over the medium term.

Bears Say

Moderate Gross MarginA 34.3% gross margin limits the upside from revenue growth because a large portion of sales goes to production and procurement. In the longer term, lower gross margins reduce incremental profitability and require continued operational improvement to sustain net margins as scale increases.

Small Operating TeamA 16-person workforce creates execution and scaling risk in regulated medicinal cannabis operations that require compliance, manufacturing scale-up and commercial expansion. Limited headcount can strain delivery, slow product development, and increase dependency on third parties.

Sustainability Of Cash SpikeAn extreme one-time jump in free cash flow can reflect timing or non-recurring items; sustaining such growth is uncertain. Over the next 2–6 months, reliance on continued cash conversion improvements is a risk if revenue or working capital patterns revert to prior norms.

Bioxyne Limited News

Bioxyne Lifts FY26 Earnings Guidance After Strong First Half

Bioxyne Limited ( ($AU:BXN) ) just unveiled an announcement. Bioxyne has upgraded its FY26 adjusted EBITDA guidance to...

3d ago

BXN

Bioxyne Profit Surges as Revenue Nearly Triples on Alternative Therapeutics Push

Bioxyne Limited ( ($AU:BXN) ) has provided an update. Bioxyne Limited reported a sharp improvement in its financial...

3d ago

BXN

Bioxyne Secures First Orders for GMP Psilocybin Capsules in Emerging Psychedelic Therapy Market

An update from Bioxyne Limited ( ($AU:BXN) ) is now available. Bioxyne Limited, through subsidiary Breathe Life Sciences,...

18d ago

BXN

Bioxyne Seeks ASX Quotation for 14.5 Million New Shares Issued Under Incentive Plan

Bioxyne Limited ( ($AU:BXN) ) has provided an announcement. Bioxyne Limited has applied for quotation on the ASX...

30d ago

BXN

Bioxyne Switches Auditor to Support International Expansion

Bioxyne Limited ( ($AU:BXN) ) has shared an announcement. Bioxyne Limited has appointed Pitcher Partners in Brisbane as...

30d ago

BXN

Bioxyne Flags Q2 FY2026 Results Presentation as Informational Only, Not Investment Offer

Bioxyne Limited ( ($AU:BXN) ) has provided an announcement. Bioxyne Limited has released a presentation of its second-quarter...

1M ago

BXN

Bioxyne Cancels Redundant ASX Notice on Lapsed Performance Rights

Bioxyne Limited ( ($AU:BXN) ) just unveiled an announcement. Bioxyne Limited has informed the ASX that it is...

1M ago

BXN

Bioxyne Increases Director Samuel Watson’s Equity Stake Through Performance Awards

Bioxyne Limited ( ($AU:BXN) ) has shared an announcement. Bioxyne Limited has reported a change in the interests...

2M ago

BXN

Bioxyne Issues 85.5 Million Unquoted Performance Rights Under Employee Incentive Scheme

Bioxyne Limited ( ($AU:BXN) ) has issued an announcement. Bioxyne Limited has issued 85.5 million unquoted performance rights...

2M ago

BXN

Bioxyne Seeks ASX Quotation for 30 Million New Shares Issued Under Employee Scheme

Bioxyne Limited ( ($AU:BXN) ) has issued an announcement. Bioxyne Limited has applied to the ASX for quotation...

2M ago

BXN

BXN FAQ

What was Bioxyne Limited’s price range in the past 12 months?

Bioxyne Limited lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.

What is Bioxyne Limited’s market cap?

Bioxyne Limited’s market cap is AU$134.39M.

When is Bioxyne Limited’s upcoming earnings report date?

Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 180 days.

How were Bioxyne Limited’s earnings last quarter?

Bioxyne Limited released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.

Is Bioxyne Limited overvalued?

According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioxyne Limited pay dividends?

Bioxyne Limited does not currently pay dividends.

What is Bioxyne Limited’s EPS estimate?

Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bioxyne Limited have?

Bioxyne Limited has 2,239,909,200 shares outstanding.

What happened to Bioxyne Limited’s price movement after its last earnings report?

Bioxyne Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.385%.

Which hedge fund is a major shareholder of Bioxyne Limited?

Currently, no hedge funds are holding shares in AU:BXN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bioxyne Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

61.21%

Trailing 12-Months

Asset Growth

192.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bioxyne Limited

Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.